Einzeltreffer — DigiBib

The spread of coronavirus diseases has resulted in a clarion call to develop potent drugs and vaccines even as different strains appear beyond human prediction. An initial step that is integral to the viral entry into host cells results from an active-targeted interaction of the viral spike (S) proteins and the cell surface receptor, called angiotensin-converting enzyme 2 (ACE2). Thus, engineered ACE2 has been an interesting decoy inhibitor against emerging coronavirus infestation. This article discusses promising innovative ACE2 engineering pathways for current and emerging coronavirus therapeutic development. First, we provide a brief discussion of some ACE2-associated human coronaviruses and their cell invasion mechanism. Then, we describe and contrast the individual spike proteins and ACE2 receptor interactions, highlighting crucial hotspots across the ACE2-associated coronaviruses. Lastly, we address the importance of multivalency in ACE2 nanomedicine engineering and discuss novel approaches to develop and achieve multivalent therapeutic outcomes. Beyond coronaviruses, these approaches will serve as a paradigm to develop new and improved treatment technologies against pathogens that use ACE2 receptor for invasion.

Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Eugene M. Obeng has patent #Engineered ACE2 and uses thereof (Provisional) pending to Monash University.

Titel:	Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development.
Autor/in / Beteiligte Person:	Obeng, EM ; Fianu, I ; Danquah, MK
Zeitschrift:	Nano today, Jg. 46 (2022-10-01), S. 101580
Veröffentlichung:	Kidlington, UK : Elsevier Ltd., 2022
Medientyp:	academicJournal
ISSN:	1748-0132 (print)
DOI:	10.1016/j.nantod.2022.101580
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Review Language: English [Nano Today] 2022 Oct; Vol. 46, pp. 101580. <i>Date of Electronic Publication: </i>2022 Aug 04. References: Nature. 2022 Jan;601(7893):410-414. (PMID: 34794169) ; Nat Rev Drug Discov. 2013 May;12(5):347-57. (PMID: 23584393) ; Science. 2020 Sep 4;369(6508):1261-1265. (PMID: 32753553) ; J Am Chem Soc. 2021 Oct 27;143(42):17615-17621. (PMID: 34647745) ; Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877) ; Chem Commun (Camb). 2013 Mar 28;49(25):2557-9. (PMID: 23423192) ; J Mol Biol. 2004 Dec 3;344(4):1051-69. (PMID: 15544812) ; J Virol. 2020 Oct 27;94(22):. (PMID: 32847856) ; Structure. 1997 Jun 15;5(6):789-98. (PMID: 9261070) ; Front Immunol. 2020 Mar 25;11:496. (PMID: 32269572) ; Nat Struct Mol Biol. 2021 Feb;28(2):202-209. (PMID: 33432247) ; ACS Appl Mater Interfaces. 2021 Dec 1;13(47):55767-55779. (PMID: 34793116) ; Lancet. 2003 Jul 26;362(9380):263-70. (PMID: 12892955) ; Nat Commun. 2020 Nov 30;11(1):6089. (PMID: 33257670) ; Angew Chem Int Ed Engl. 2001 Jun 1;40(11):2004-2021. (PMID: 11433435) ; Mol Ther. 2021 Jul 7;29(7):2219-2226. (PMID: 33992805) ; Cell Commun Signal. 2014 Apr 11;12:26. (PMID: 24725987) ; J Infect Dis. 2022 Aug 24;226(2):195-198. (PMID: 35356987) ; Adv Drug Deliv Rev. 2021 Feb;169:1-21. (PMID: 33264593) ; Trends Biotechnol. 2010 Jul;28(7):355-62. (PMID: 20447706) ; Lancet. 2013 Dec 14;382(9909):1993-2002. (PMID: 24055451) ; Nat Nanotechnol. 2013 Feb;8(2):137-43. (PMID: 23334168) ; Cell Death Differ. 2021 Feb;28(2):626-639. (PMID: 33479399) ; Hypertension. 2010 Jan;55(1):90-8. (PMID: 19948988) ; EMBO Mol Med. 2012 Oct;4(10):1015-28. (PMID: 22837174) ; Ther Deliv. 2012 Oct;3(10):1171-87. (PMID: 23116010) ; Nature. 2021 Jul;595(7869):718-723. (PMID: 34082438) ; J Am Chem Soc. 2021 Aug 11;143(31):12194-12201. (PMID: 34291944) ; J Extracell Vesicles. 2020 Dec;10(2):e12050. (PMID: 33391636) ; J Biol Chem. 2010 Apr 9;285(15):11039-44. (PMID: 20147747) ; J Biochem. 2021 Oct 11;170(2):299-306. (PMID: 33774672) ; Lancet Public Health. 2021 Jun;6(6):e416-e427. (PMID: 33991482) ; Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19970-4. (PMID: 19901337) ; Front Cell Infect Microbiol. 2020 Dec 08;10:589505. (PMID: 33364201) ; Crit Rev Biotechnol. 2015 Jun;35(2):235-54. (PMID: 24156398) ; Acta Pharmacol Sin. 2020 Sep;41(9):1255-1257. (PMID: 32581256) ; J Virol. 2015 Jul;89(14):7202-13. (PMID: 25926653) ; Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27141-27147. (PMID: 33024017) ; Nat Med. 2021 Aug;27(8):1385-1394. (PMID: 34272499) ; Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14265-70. (PMID: 18809927) ; Nat Rev Immunol. 2021 Oct;21(10):626-636. (PMID: 34373623) ; Front Bioeng Biotechnol. 2020 Apr 03;8:166. (PMID: 32309278) ; Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4146-51. (PMID: 22315426) ; Nat Commun. 2018 Mar 6;9(1):960. (PMID: 29511190) ; Nature. 2020 Jun;582(7811):230-233. (PMID: 32499650) ; MAbs. 2020 Jan-Dec;12(1):1752529. (PMID: 32316838) ; Emerg Infect Dis. 2005 Aug;11(8):1225-9. (PMID: 16102311) ; Mayo Clin Proc. 2020 Aug;95(8):1701-1703. (PMID: 32753142) ; Lancet Infect Dis. 2021 Feb;21(2):e26-e35. (PMID: 33125914) ; Sci Rep. 2021 May 19;11(1):10617. (PMID: 34012108) ; J Infect Dis. 2005 Feb 15;191(4):503-6. (PMID: 15655772) ; Nat Microbiol. 2020 Oct;5(10):1185-1191. (PMID: 32908214) ; Nanotoxicology. 2016 Nov;10(9):1385-94. (PMID: 27465202) ; J Extracell Vesicles. 2015 Apr 20;4:26316. (PMID: 25899407) ; J Biol Chem. 2015 Mar 27;290(13):8166-72. (PMID: 25657008) ; JAMA. 2021 Apr 6;325(13):1241-1243. (PMID: 33729423) ; J Extracell Vesicles. 2020 Sep 6;9(1):1816710. (PMID: 33133429) ; Int J Nanomedicine. 2022 Feb 11;17:665-680. (PMID: 35185331) ; Biomed Pharmacother. 2021 Jul;139:111541. (PMID: 33848776) ; Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149. (PMID: 32747721) ; J Phys Chem B. 2021 Jul 8;125(26):7101-7107. (PMID: 34110159) ; Nature. 2020 Aug;584(7821):353-363. (PMID: 32659783) ; J Virol. 2018 Jan 17;92(3):. (PMID: 29142129) ; Nat Rev Microbiol. 2021 Mar;19(3):155-170. (PMID: 33116300) ; Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444) ; Angew Chem Int Ed Engl. 2019 Aug 19;58(34):11763-11767. (PMID: 31240809) ; Annu Rev Virol. 2016 Sep 29;3(1):237-261. (PMID: 27578435) ; Bioeng Transl Med. 2017 May 22;2(2):180-190. (PMID: 28932819) ; Adv Drug Deliv Rev. 2009 Jun 21;61(6):428-37. (PMID: 19376175) ; ACS Nano. 2020 Mar 24;14(3):2569-2574. (PMID: 32129977) ; Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8709-8714. (PMID: 30975744) ; Adv Sci (Weinh). 2021 Nov;8(21):e2100460. (PMID: 34494387) ; Nature. 2003 Nov 27;426(6965):450-4. (PMID: 14647384) ; Cell Rep. 2020 Dec 22;33(12):108528. (PMID: 33326798) ; Nat Commun. 2022 Jan 20;13(1):405. (PMID: 35058437) ; Nat Commun. 2021 Dec 20;12(1):7345. (PMID: 34930910) ; ACS Nano. 2014 Jun 24;8(6):5725-37. (PMID: 24848786) ; Nat Chem. 2016 Feb;8(2):120-8. (PMID: 26791894) ; Science. 2017 Feb 10;355(6325):597-602. (PMID: 28183972) ; Science. 2006 Mar 24;311(5768):1740-3. (PMID: 16556836) ; Adv Mater. 2018 Jun;30(23):e1706759. (PMID: 29582476) ; Nat Biotechnol. 2011 Apr;29(4):341-5. (PMID: 21423189) ; Front Immunol. 2018 Jan 08;8:1860. (PMID: 29375551) ; J Virol. 2015 Feb;89(4):1954-64. (PMID: 25428871) ; Cell Res. 2021 Jan;31(1):98-100. (PMID: 33177651) ; NPJ Vaccines. 2021 May 13;6(1):70. (PMID: 33986287) ; Proc Natl Acad Sci U S A. 2022 Jan 4;119(1):. (PMID: 34937699) ; Science. 2020 May 1;368(6490):473-474. (PMID: 32303591) ; Nat Struct Mol Biol. 2019 Jun;26(6):481-489. (PMID: 31160783) ; Nature. 2017 Oct 4;550(7674):53-60. (PMID: 28980641) ; Matter. 2021 Jun 2;4(6):2059-2082. (PMID: 33907732) ; Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53. (PMID: 15496474) ; J Extracell Vesicles. 2017 Jun 6;6(1):1324730. (PMID: 28717420) ; Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93. (PMID: 15897467) ; Nat Commun. 2021 Jun 28;12(1):3991. (PMID: 34183681) ; EMBO Mol Med. 2010 Jul;2(7):247-57. (PMID: 20597104) ; Nat Nanotechnol. 2021 Aug;16(8):942-951. (PMID: 34140674) ; Nat Hum Behav. 2021 Nov;5(11):1528-1534. (PMID: 34002053) ; Biochemistry. 2009 Jul 21;48(28):6571-84. (PMID: 19485420) ; N Engl J Med. 2020 Dec 3;383(23):2255-2273. (PMID: 33264547) ; Chembiochem. 2009 Mar 23;10(5):787-98. (PMID: 19199328) ; Sci Adv. 2021 Jan 1;7(1):. (PMID: 33277323) ; Sci Rep. 2011;1:124. (PMID: 22355641) ; Nano Today. 2021 Feb;36:101012. (PMID: 33139972) ; ACS Cent Sci. 2016 Sep 28;2(9):637-646. (PMID: 27725962) ; J Biol Chem. 2002 Apr 26;277(17):14838-43. (PMID: 11815627) ; Science. 2020 May 8;368(6491):630-633. (PMID: 32245784) ; Curr Opin Virol. 2014 Apr;5:58-62. (PMID: 24584035) ; ACS Synth Biol. 2012 Jun 15;1(6):240-50. (PMID: 23651206) ; Virol J. 2004 Nov 17;1:7. (PMID: 15548333) ; Nat Chem Biol. 2007 Nov;3(11):707-8. (PMID: 17891153) ; Nat Commun. 2021 Mar 1;12(1):1346. (PMID: 33649323) ; Commun Biol. 2021 Sep 2;4(1):1031. (PMID: 34475514) ; Nature. 2013 Mar 14;495(7440):251-4. (PMID: 23486063) ; Nanomedicine (Lond). 2019 Apr;14(7):797-801. (PMID: 30895871) ; Sci Rep. 2021 Jun 17;11(1):12740. (PMID: 34140558) ; Nanoscale. 2017 Jun 29;9(25):8858-8870. (PMID: 28632260) ; J Infect Dis. 2019 Feb 15;219(5):829-835. (PMID: 30256968) ; Matter. 2022 Jan 5;5(1):336-362. (PMID: 34693277) ; J Chem Inf Model. 2021 Sep 27;61(9):4656-4669. (PMID: 34427448) ; iScience. 2022 Jan 21;25(1):103670. (PMID: 34957381) ; J Virol. 2006 Sep;80(17):8639-52. (PMID: 16912312) ; Nature. 2020 Nov;587(7835):657-662. (PMID: 32726803) ; Nat Chem. 2012 Feb 05;4(4):298-304. (PMID: 22437715) ; Emerg Infect Dis. 2004 Feb;10(2):339-41. (PMID: 15030708) ; J Virol. 2013 Oct;87(19):10777-83. (PMID: 23903833) ; Adv Mater. 2021 Dec;33(49):e2103471. (PMID: 34665481) ; Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):5733-5740. (PMID: 32123103) ; EMBO Mol Med. 2021 Jan 11;13(1):e12828. (PMID: 33159417) ; Nat Commun. 2017 Sep 27;8(1):709. (PMID: 28955033) ; Adv Mater. 2018 Nov;30(45):e1802233. (PMID: 30252965) ; Int J Biol Macromol. 2020 Dec 15;165(Pt B):1626-1633. (PMID: 33080267) ; Antiviral Res. 2021 Dec;196:105197. (PMID: 34774603) ; Mol Cell Proteomics. 2020 May;19(5):757-773. (PMID: 32127388) ; J Biol Chem. 2014 Aug 1;289(31):21617-26. (PMID: 24951593) ; Elife. 2020 Apr 06;9:. (PMID: 32250244) ; Nanomedicine (Lond). 2016 Jan;11(1):81-100. (PMID: 26653875) ; J Nanobiotechnology. 2021 Aug 12;19(1):242. (PMID: 34384440) ; Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4025-6. (PMID: 22378650) ; Acta Biomater. 2021 Jul 15;129:57-72. (PMID: 34048973) ; Nat Commun. 2021 Jun 21;12(1):3802. (PMID: 34155214) ; Theranostics. 2022 Mar 6;12(6):2639-2657. (PMID: 35401811) ; JAMA. 2020 Feb 25;323(8):707-708. (PMID: 31971553) ; Cell Discov. 2021 Aug 12;7(1):65. (PMID: 34385423) ; Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2681-2690. (PMID: 30679277) ; MAbs. 2011 Sep-Oct;3(5):415-6. (PMID: 21785279) ; EMBO J. 2002 Nov 1;21(21):5587-98. (PMID: 12411477) ; Nat Rev Chem. 2019 Jun;3(6):393-400. (PMID: 33834115) ; J Biol Chem. 2001 Aug 31;276(35):33220-32. (PMID: 11431476) ; Arch Toxicol. 2019 Apr;93(4):871-885. (PMID: 30838431) ; Nature. 2005 Jul 7;436(7047):112-6. (PMID: 16001071) ; Lancet Infect Dis. 2014 Feb;14(2):100-1. (PMID: 24457167) ; Adv Colloid Interface Sci. 2007 Oct 31;134-135:167-74. (PMID: 17574200) ; Annu Rev Cell Dev Biol. 2018 Oct 6;34:163-188. (PMID: 30110557) ; ACS Nano. 2021 Apr 27;15(4):6340-6351. (PMID: 33734675) ; Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734. (PMID: 32376634) ; FEBS J. 2005 Jul;272(14):3512-20. (PMID: 16008552) ; Water Res. 2021 Feb 15;190:116742. (PMID: 33348070) ; Nat Biotechnol. 2022 Aug;40(8):1259-1269. (PMID: 35301496) ; Proteomics. 2018 Sep;18(17):e1800266. (PMID: 30035390) ; Antiviral Res. 2021 Oct;194:105147. (PMID: 34375715) ; Signal Transduct Target Ther. 2020 Jun 10;5(1):89. (PMID: 32533062) ; Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):. (PMID: 33833059) ; Nature. 2015 Oct 1;526(7571):118-21. (PMID: 26374997) ; iScience. 2020 Aug 21;23(8):101400. (PMID: 32738607) ; Nat Rev Microbiol. 2013 Dec;11(12):836-48. (PMID: 24217413) ; PLoS One. 2009;4(4):e5009. (PMID: 19347043) ; Nat Nanotechnol. 2013 May;8(5):336-40. (PMID: 23584215) ; Nat Rev Microbiol. 2009 Jun;7(6):439-50. (PMID: 19430490) ; Lancet. 2004 Mar 20;363(9413):938-47. (PMID: 15043961) ; Nat Rev Immunol. 2020 Jun;20(6):339-341. (PMID: 32317716) ; Front Med (Lausanne). 2021 Jan 14;7:594439. (PMID: 33585502) ; Biochem J. 2016 Aug 15;473(16):2463-9. (PMID: 27274088) ; Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):. (PMID: 34292870) ; Nat Commun. 2021 Jul 26;12(1):4598. (PMID: 34312390) ; Nat Commun. 2020 Apr 24;11(1):2070. (PMID: 32332765) ; Sci Adv. 2022 Jul 15;8(28):eabn4188. (PMID: 35857504) ; Cell Res. 2013 Aug;23(8):986-93. (PMID: 23835475) ; J Biol Chem. 2006 Feb 10;281(6):3198-203. (PMID: 16339146) ; Science. 2022 Mar 4;375(6584):1048-1053. (PMID: 35133176) ; Nano Lett. 2014;14(4):2181-8. (PMID: 24673373) ; J Extracell Vesicles. 2015 May 14;4:27066. (PMID: 25979354) ; ACS Appl Mater Interfaces. 2022 Feb 2;14(4):4882-4891. (PMID: 35067058) ; Nat Rev Immunol. 2020 Oct;20(10):633-643. (PMID: 32782358) ; Science. 2005 Sep 16;309(5742):1864-8. (PMID: 16166518) ; Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. (PMID: 32253318) ; Materials (Basel). 2021 Mar 28;14(7):. (PMID: 33800633) ; Nat Commun. 2021 Jan 22;12(1):542. (PMID: 33483491) ; Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5. (PMID: 21690347) ; Nat Med. 2004 Apr;10(4):368-73. (PMID: 15034574) ; Emerg Infect Dis. 2003 Nov;9(11):1453-4. (PMID: 14718090) ; Signal Transduct Target Ther. 2020 Dec 4;5(1):283. (PMID: 33277466) ; Front Med (Lausanne). 2020 May 22;7:248. (PMID: 32574336) ; Signal Transduct Target Ther. 2022 Jan 11;7(1):10. (PMID: 35013100) ; N Engl J Med. 2013 Aug 1;369(5):407-16. (PMID: 23782161) ; J Mol Biol. 1997 May 2;268(2):424-48. (PMID: 9159481) ; Langmuir. 2012 Jun 26;28(25):9673-9. (PMID: 22524519) ; Nature. 2020 Mar;579(7798):260-264. (PMID: 32132711) ; Nat Commun. 2020 Jul 9;11(1):3523. (PMID: 32647131) ; Bioconjug Chem. 2015 Dec 16;26(12):2419-28. (PMID: 26505780) ; Nat Rev Dis Primers. 2019 Mar 14;5(1):18. (PMID: 30872586) ; J Biol Chem. 2004 Apr 23;279(17):17996-8007. (PMID: 14754895) ; Int J Mol Sci. 2021 Aug 19;22(16):. (PMID: 34445651) ; Oncogene. 2001 May 10;20(21):2611-7. (PMID: 11420672) ; Nat Commun. 2021 Jan 4;12(1):29. (PMID: 33397962) ; Science. 2020 Jul 17;369(6501):330-333. (PMID: 32366695) ; Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20. (PMID: 34611326) ; Kidney Int. 2018 Jul;94(1):114-125. (PMID: 29691064) ; Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28046-28055. (PMID: 33093202) ; Sci Adv. 2021 Feb 17;7(8):. (PMID: 33597251) ; Pneumonia (Nathan). 2021 Dec 6;13(1):14. (PMID: 34872623) ; J Phys Chem B. 2023 Mar 9;127(9):1995-2001. (PMID: 36827526) ; PLoS Pathog. 2018 Aug 13;14(8):e1007236. (PMID: 30102747) ; Protein Cell. 2018 Jan;9(1):63-73. (PMID: 28986820) ; Biochemistry. 2006 Dec 26;45(51):15205-15. (PMID: 17176042) ; J Extracell Vesicles. 2016 Mar 14;5:31053. (PMID: 26979463) ; Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11488-11493. (PMID: 29073076) ; J Mater Chem B. 2016 Mar 21;4(11):2008-2016. (PMID: 32263078) ; Nat Biotechnol. 2020 Nov;38(11):1226-1228. (PMID: 33144725) ; J Am Chem Soc. 2003 Dec 31;125(52):16271-84. (PMID: 14692768) ; Trends Biotechnol. 2018 Jan;36(1):10-14. (PMID: 29074309) ; ACS Nano. 2017 Dec 26;11(12):11773-11776. (PMID: 29206030) ; Nat Nanotechnol. 2018 Dec;13(12):1182-1190. (PMID: 30177807) ; Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651) ; Sci Transl Med. 2019 May 15;11(492):. (PMID: 31092696) ; Virology. 2007 Oct 25;367(2):367-74. (PMID: 17631932) ; Lancet. 2003 May 24;361(9371):1773-8. (PMID: 12781536) ; J Extracell Vesicles. 2022 Jan;11(1):e12179. (PMID: 34982509) ; Acta Pharm Sin B. 2022 Mar;12(3):1523-1533. (PMID: 34522576) ; Biotechnol Prog. 2007 Mar-Apr;23(2):316-9. (PMID: 17335286) ; Chembiochem. 2016 May 17;17(10):883-5. (PMID: 26928847) ; Cell. 2020 May 14;181(4):905-913.e7. (PMID: 32333836) ; Proteins. 2021 Sep;89(9):1065-1078. (PMID: 33973262) ; J Mol Biol. 2001 Mar 9;306(5):1099-114. (PMID: 11237620) ; Nat Commun. 2021 Jun 16;12(1):3661. (PMID: 34135340) ; Nature. 2020 May;581(7807):215-220. (PMID: 32225176) ; Elife. 2021 Dec 20;10:. (PMID: 34927585) ; Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):. (PMID: 33833058) ; Annu Rev Biochem. 2010;79:413-44. (PMID: 20307192) ; Mol Ther. 2013 Jan;21(1):185-91. (PMID: 23032975) ; Cell Mol Immunol. 2020 Jul;17(7):765-767. (PMID: 32047258) ; Nano Lett. 2020 Jul 8;20(7):5570-5574. (PMID: 32551679) ; Nat Chem Biol. 2022 Mar;18(3):342-351. (PMID: 35046611) ; ACS Nano. 2017 Jan 24;11(1):69-83. (PMID: 28068069) ; Front Cell Dev Biol. 2016 Sep 12;4:97. (PMID: 27672635) ; Nanotoxicology. 2021 Dec;15(10):1331-1357. (PMID: 35061957) ; Diabetes. 2018 Apr;67(4):704-716. (PMID: 29386225) ; Clin Pharmacokinet. 2013 Sep;52(9):783-92. (PMID: 23681967) Contributed Indexing: Keywords: ACE2 therapeutics; Coronaviruses; Extracellular vesicles; Multivalency; Nanomedicines; SARS-CoV-2 Entry Date(s): Date Created: 20220809 Latest Revision: 20231101 Update Code: 20231215 PubMed Central ID: PMC9350675

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development.